West Pharmaceutical Services

West Pharmaceutical Services

Prezzo: 328.82

Società e modello di business

West Pharmaceutical Services is a leading provider of innovative solutions for injectable drug delivery and containment. The company specializes in manufacturing components and systems for the pharmaceutical and biotechnology industries, including prefillable syringes, vials, and other packaging solutions. Major business segments include Pharmaceutical Packaging Systems and Contract Manufacturing. The primary revenue sources are sales of these products to pharmaceutical companies and contract services for drug development and manufacturing.

Profilo di investimento

The investment profile of West Pharmaceutical Services is more aligned with growth investors, given its focus on innovation and expanding market presence. The company demonstrates solid revenue growth and a relatively low dividend yield, indicating a reinvestment strategy. This profile may appeal to those seeking long-term capital appreciation rather than immediate income.

Sito ufficiale

Metriche fondamentali (sperimentale)

EPS (TTM) — utile per azione degli ultimi 12 mesi, $
7.52 OK
Ricavi QoQ — crescita dei ricavi trimestre su trimestre
5.0%
Sorpresa EPS
26.8% meglio del previsto
Volatilità 20g
1.6% stabile
Rendimento dividendo
0.3% basso ultima data ex-dividendo: 2026-04-29
Dati FMP / FinFeed aggiornati: 2026-06-13
Racc.: Compra Potenziale: 72 Rischio: 30 Aggiornato: 2026-06-13 02:56
Come funziona la raccomandazione
Perché l'AI la pensa così:
Strong momentum and solid fundamentals support growth potential.

Traccia in portafoglio

Grafico prezzo

Raccomandazione AI Previsione analista Evento calendario Segnale positivo Segnale negativo Neutrale / aggiornamento Mantieni / informativo B My buy S My sell
Cambiamenti di raccomandazione AI
Data Prima Dopo Motivo
2026-05-16 02:45 Mantieni Compra Strong fundamentals, but recent volatility raises concerns.
2026-05-08 15:20 Mantieni Strong momentum and positive EPS surprise support growth outlook.
2026-05-04 02:37 Mantieni Compra Компания демонстрирует сильный рост выручки и положительные финансовые результаты, что указывает на хорошие перспективы. Низкий дивидендный доход и умеренный риск делают акцию привлекательной для долгосрочных инвестиций.
Previsioni analisti
Data Analista Action Target Prezzo allora
2026-06-09 10:24 Barclays Aggiorna — → 400 319.75
2026-04-27 12:36 Morgan Stanley Target alzato 285 → 315 306.39001
2026-04-27 10:04 Barclays Target alzato 275 → 310 306.16

Ancora nulla